weiss
rc
oostromram
inhibitori
effect
ribavirin
alon
combin
human
alpha
interferon
felin
infecti
periton
viru
replic
vitro
vet
microbiol
antivir
activ
ribavirin
virazol
either
alon
combin
recombin
human
leukocyt
alpha
interferon
rhuifna
evalu
felin
infecti
periton
viru
fipv
felin
kidneycel
cultur
inhibitori
dose
ido
ribavirin
uninfect
rapidli
divid
cell
bg
wherea
ido
fipv
g
therapeut
index
ti
ribavirin
ie
ratio
minimum
celltox
dose
minimum
virusinhibitori
dose
although
dosedepend
inhibit
viral
infect
occur
nontox
dose
maximum
antivir
effect
loglo
reduct
fipv
occur
cytotox
dose
low
moder
dose
ribavirin
combin
either
u
rhuifna
result
antivir
effect
significantli
greater
sum
observ
effect
either
ribavirin
rhuifna
alon
signific
synergist
interact
rhuifna
occur
ribavirin
dose
synergist
combin
rhuifna
ribavirin
produc
rel
increas
fipv
antivir
activ
compar
produc
equival
dose
respect
ribavirin
rhuifna
alon
cell
growth
studi
addit
either
u
rhuifnc
test
dose
ribavirin
increas
anticellular
effect
observ
ribavirin
alon
seemingli
potenti
ribavirin
antivir
activ
rhuifna
independ
addit
cytotox
effect
potenti
synergist
combin
two
antivir
agent
vivo
may
decreas
therapeut
dose
ribavirin
requir
inhibit
fipv
thu
reduc
drug
toxic
present
antivir
drug
known
clinic
effect
felin
infecti
periton
fip
fatal
immunopatholog
diseas
cat
induc
coronaviru
fipv
pedersen
scott
studi
vitro
sensit
fipv
antivir
agent
limit
far
evalu
felin
human
interferon
ifn
weiss
toiviokinnucan
recommend
virus
white
fenner
ration
approach
toward
develop
antivir
agent
clinic
use
cat
fip
would
screen
potenti
compound
first
vitro
prefer
host
speci
cell
agent
show
rel
high
therapeut
index
ti
ratio
minimum
celltox
dose
minimum
virusinhibitori
dose
would
select
test
includ
toxicolog
clinic
efficaci
studi
preliminari
vitro
studi
one
promis
synthet
antivir
fipv
ribavirin
virazol
ribavirin
nucleosid
analogu
relat
guanosin
demonstr
broadspectrum
virostat
activ
dna
rna
virus
includ
herp
orthomyxo
paramyxo
arena
bunya
virus
nicholson
rein
gross
bryson
due
potenti
toxic
clinic
applic
ribavirin
human
limit
mostli
aerosol
therapi
infant
seriou
respiratori
syncyti
viru
infect
intraven
oral
administr
adult
influenza
acut
hemorrhag
fever
eg
lassa
junin
machupo
viru
infect
rein
gross
bryson
besid
broadspectrum
activ
promin
attribut
ribavirin
lack
develop
viral
resist
nicholson
although
ribavirin
show
strong
activ
fipv
pilot
studi
cytotox
felin
cell
modest
ti
suggest
toxic
administ
therapeut
cat
combin
differ
antivir
drug
notabl
human
ifn
acyclovir
produc
addit
synergist
antivir
effect
vitro
human
herpesvirus
levin
leari
stanwick
et
al
spector
et
al
suggest
similar
interact
vivo
might
allow
smaller
dose
drug
use
decreas
potenti
advers
clinic
effect
enhanc
efficaci
bryson
anticip
combin
ribavirin
human
ifn
drug
inhibit
fipv
vitro
weiss
toiviokinnucan
might
show
addit
synergist
inhibitori
effect
fipv
use
clinic
object
present
studi
document
antivir
activ
ribavirin
fipv
vitro
evalu
potenti
addit
synergist
effect
ribavirin
combin
human
ifnc
replic
fipv
felin
cell
cultur
crandel
felin
kidney
crfk
cell
crandel
despeaux
maintain
growth
medium
gm
consist
minimum
essenti
medium
gibco
gm
supplement
heatinactiv
fetal
bovin
serum
u
penicillin
streptomycin
g
amphotericin
along
mm
lglutamin
nonessenti
amino
acid
cultur
incub
humidifi
chamber
atmospher
air
virul
fipv
strain
pedersen
et
al
obtain
dr
nc
pedersen
univers
california
davi
ca
passag
seven
time
crfk
laboratori
viral
suspens
prepar
supernat
fluid
thrice
frozenthaw
cell
harvest
cytopath
effect
cpe
frozen
store
aliquot
c
use
infect
titer
fipv
stock
tissuecultur
infecti
dose
tcidso
ribavirin
virazol
viratek
co
lot
initi
store
lyophil
g
dilut
use
stock
solut
ribavirin
prepar
gm
sterilefilt
cellulos
acet
membran
nalgen
frozen
store
aliquot
week
use
recombin
dnaderiv
bglii
restrict
endonucleas
specifi
human
leukocyt
alpha
hybrid
subtyp
ifn
rhuifna
hoffo
manlaroch
lot
ro
gift
dr
r
cordt
roch
laboratori
nutley
nj
store
lyophil
concentr
intern
unit
u
per
vial
dilut
gm
sterilefilt
use
antivir
activ
u
rhuifna
determin
manufactur
laboratori
use
intern
refer
standard
human
leukocyt
ifn
inhibitori
effect
ribavirin
rhuifna
combin
normal
rapidli
divid
crfk
cell
evalu
use
cellprolifer
assay
describ
previous
levin
leari
briefli
e
cellcultur
flask
corn
seed
fresh
trypsin
crfk
cell
flask
incub
c
h
seed
cell
monolay
confluent
medium
ml
remov
flask
replac
equal
volum
either
gm
cell
control
ribavirin
rhuifn
drug
combin
cultur
incub
examin
daili
phasecontrast
light
microscopi
cytopath
effect
cpe
h
drug
exposur
triplic
control
drugtreat
flask
inhibitor
concentr
trypsin
number
viabl
cell
flask
determin
trypan
blue
exclus
count
duplic
use
neubauer
hemocytomet
inhibitori
effect
ribavirin
alon
combin
rhuifna
fipv
replic
measur
use
microtitr
infect
cpe
inhibit
assay
describ
previous
ifn
weiss
toiviokinnucan
antivir
assay
ribavirin
serial
loglo
dilut
fipv
made
gm
ml
dilut
ad
triplic
well
microtitr
plate
flow
contain
monolay
cultur
crfk
cell
h
viral
adsorpt
c
inoculum
remov
well
replenish
ml
gm
viru
control
gm
contain
differ
concentr
ribavirin
cultur
incub
examin
h
viral
cpe
endpoint
infect
titer
express
loglo
tcidso
per
ml
fipv
calcul
use
method
reed
muench
antivir
activ
ribavirin
determin
loglo
differ
titer
viru
control
ribavirintr
cultur
antivir
assay
rhuifna
combin
ribavirin
rhuifnc
ident
procedur
describ
ribavirin
follow
except
rhuifn
u
ad
cultur
ml
per
well
h
h
viral
adsorpt
alon
combin
cultur
equal
ml
volum
ribavirin
uninfect
cultur
expos
dose
ribavirin
rhuifnc
combin
includ
drug
toxic
control
order
evalu
combin
effect
two
antivir
drug
cell
cultur
adapt
criteria
drug
combin
describ
previous
valeriot
lin
rel
decreas
control
titer
ya
antivir
drug
defin
reduct
viru
titer
produc
presenc
drug
rel
control
without
drug
similarli
yab
observ
titer
control
decreas
presenc
drug
rel
control
without
drug
calcul
titer
control
decreas
yc
addit
interact
product
ya
yb
yyxyb
therefor
log
yc
equal
algebra
sum
loglo
ya
loglo
yb
loglo
yc
loglo
ya
qloglo
yb
thu
synergist
interact
yab
yc
yab
yo
greater
effect
agent
alon
interact
consid
subaddit
yab
less
effect
agent
alon
greater
least
effect
agent
interfer
yab
less
least
effect
agent
alon
antagon
interact
inhibit
produc
equival
effect
agent
alon
consid
indiffer
analysi
data
perform
use
computer
statist
analysi
program
abstat
andersonbel
correl
viabl
cell
count
ribavirin
concentr
made
multipl
linear
regress
analysi
loglo
correct
mean
cell
valu
statist
test
differ
mean
fipv
titer
reduct
combin
drug
yab
ribavirin
alon
yab
yc
synergist
interact
perform
use
student
ttest
pair
sampl
student
ttest
also
use
compar
mean
cell
number
untreat
vs
drugtreat
ribavirintr
vs
combin
drugtreat
cultur
compar
viabl
cell
number
untreat
crfk
cell
number
cell
cultur
treat
ribavirin
dose
rang
g
reduc
fig
mean
loglo
cell
number
ribavirintr
cultur
relat
invers
r
p
drug
concentr
dose
ribavirin
inhibit
mean
control
cell
number
untreat
cultur
inhibitori
dose
ido
morpholog
mild
toxic
chang
consist
villou
membran
project
strand
cytoplasm
initi
observ
dose
chang
moder
mark
dose
g
accompani
round
detach
cell
small
gap
cell
monolay
fig
ido
ribavirin
fipv
approxim
g
ti
ribavirin
fipvinfect
crfk
cell
maxim
inhibit
viru
loglo
tcido
occur
ribavirin
dose
zg
inhibitori
dose
howev
often
produc
mild
moder
cpe
uninfect
crfk
cell
complet
inhibit
fipv
ribavirin
achiev
multipl
infect
moi
sinc
higher
antivir
dose
ribavirin
potent
rhuifnc
titer
control
decreas
observ
combin
drug
yab
evalu
statist
decreas
titer
obtain
ribavirin
alon
yib
virin
combin
ribavirin
rhuifnc
test
significantli
p
effect
inhibit
fipv
equival
dose
ribavirin
alon
tabl
except
lowest
dose
pg
ribavirin
combin
u
rhuifnc
ml
drug
combin
also
effect
equival
amount
rhuifnc
alon
drug
interact
observ
decreas
fipv
titer
control
combin
rhuifnc
ribavirin
significantli
greater
p
calcul
decreas
titer
addit
interact
loglo
yab
yc
tabl
synergist
drug
interact
occur
dose
u
rhuifn
ml
combin
ttg
ribavirin
dose
u
rhuifn
combin
pg
ribavirin
compar
equival
dose
individu
drug
combin
ribavirin
rhuifn
dose
lg
u
respect
produc
increas
fipv
antivir
activ
similarli
combin
ttg
ribavirin
u
rhuifnc
provid
increas
antivir
activ
compar
equival
dose
ribavirin
produc
increas
activ
compar
equival
dose
rhuifn
except
increas
antivir
effect
vs
u
rhuifn
combin
zg
ribavirin
ml
increas
rhuifn
concentr
u
minim
effect
logo
increas
magnitud
viral
inhibit
produc
synergist
drug
combin
ribavirin
dose
either
alon
combin
u
rhuifn
inhibit
growth
uninfect
rapidli
divid
crfk
cell
tabl
rhuifnc
alon
cytosuppress
addit
either
u
rhuifnc
test
dose
ribavirin
increas
anticellular
effect
produc
ribavirin
alon
p
discuss
ideal
agent
screen
vitro
antivir
activ
particular
viru
demonstr
signific
inhibit
viru
minimum
toxic
normal
host
cell
agent
ti
least
prefer
much
higher
consid
evalu
white
fenner
present
studi
found
ribavirin
produc
dosedepend
inhibit
fipv
antivir
idso
despit
good
antivir
activ
drug
suppress
normal
rapidli
divid
felin
cell
rel
low
concentr
anticellular
ido
zg
consequ
calcul
ti
ribavirin
fipv
somewhat
smaller
minim
valu
recommend
justifi
test
reason
rel
sensit
felin
cell
ribavirin
clear
ribavirin
modest
inhibitori
effect
normal
cell
cellular
dna
synthesi
also
cap
messeng
rna
sidwel
white
drug
cytotox
rest
cell
line
speci
concentr
g
sidwel
rel
toxic
ribavirin
rest
vs
divid
felin
cell
howev
determin
studi
precis
mechan
respons
antivir
action
ribavirin
welldefin
may
differ
differ
group
virus
dolin
ribavirin
analogu
guanosin
may
exert
antivir
lesser
degre
anticellular
effect
reduc
intracellular
guanosin
nucleotid
pool
therebi
inhibit
dna
rna
synthesi
ribavirin
may
also
inhibit
enzym
mrna
guanylyltransferas
respons
cap
viral
mrna
therebi
interf
translat
promot
suscept
viral
mrna
endonucleas
white
consid
antivir
activ
ribavirin
observ
us
fipv
decid
investig
potenti
addit
antivir
cytotox
effect
ribavirin
combin
rhuifnc
rational
test
combin
rhuifn
ribavirin
base
two
find
firstli
synergist
effect
human
ifn
combin
antivir
agent
acyclovir
ganciclovir
dhpg
report
herpesvirus
stanwick
et
ah
levin
leari
eppstein
et
al
secondli
rhuifn
antivir
activ
fipv
weiss
toiviokinnucan
unlik
antivir
mechan
ribavirin
ifn
produc
antivir
state
uninfect
cell
primarili
induc
enzym
polymeras
eventu
promot
degrad
viral
mrna
endonucleas
jacobsen
potenti
combin
drug
differ
antivir
action
case
ribavirin
rhuifn
could
enhanc
sum
effect
produc
agent
alon
ie
drug
synerg
ideal
clinic
efficaci
would
increas
advers
effect
drug
reduc
present
studi
dual
combin
ribavirin
even
dose
low
g
rhuifn
produc
signific
synergist
antivir
effect
fipv
vitro
moreov
antivir
effect
combin
greater
effect
drug
alon
drug
appear
compat
ie
ribavirin
antagon
interfer
antivir
state
induc
previous
rhuifn
convers
rhuifn
alter
subsequ
action
ribavirin
infect
cell
addit
rhuifn
dose
ribavirin
increas
anticellular
effect
ribavirin
alon
suggest
enhanc
ribavirin
activ
rhuifnc
independ
addit
cytotox
effect
although
antivir
dose
ribavirin
rhuifna
use
studi
vitro
viru
inhibit
assay
ifn
given
preand
postinfect
still
appropri
consid
clinic
applic
drug
combin
cat
infect
fipv
gener
ifn
consid
protect
cell
virus
still
activ
although
consider
less
given
postinfect
may
inde
act
differ
virusinfect
cell
munoz
carrasco
signific
antivir
activ
rhuifna
synergist
interact
acyclovir
observ
felin
herpesviru
rhuifna
given
postinfect
weiss
also
addit
effect
acyclovir
rhuifnfl
given
postinfect
human
cytomegaloviru
report
spector
et
al
reason
antivir
synergist
addit
activ
ifn
postinfect
clear
possibl
ifn
produc
antivir
state
uninfect
cell
popul
particularli
cultur
infect
low
moi
describ
murin
retrovirus
may
affect
posttransl
event
viru
assembl
releas
billiau
et
al
friedman
chang
potenti
combin
antivir
effect
ribavirin
rhuifna
could
enhanc
vivo
certain
immunomodulatori
action
ifn
believ
import
viru
kill
activ
macrophag
increas
cytotox
natur
killer
cell
cytotox
tlymphocyt
white
